Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 8/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904582 | 0.86 | NOS1 (0.41) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL904430 | 0.85 | TPSAB1 (0.48) | CYP2D6CYP2C9GRIN2BCYP19A1 | |
| SCHEMBL904440 | 0.83 | BCHE (0.38) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL904628 | 0.83 | TPSAB1 (0.47) | CYP2D6CYP2C9GRIN2BCYP19A1 | |
| SCHEMBL904644 | 0.83 | MAPT (0.50) | CYP2D6CYP2C9GRIN2BCYP19A1 | |
| SCHEMBL904546 | 0.82 | NOS2 (0.53) | CYP2D6CYP2C9GRIN2B | |
| SCHEMBL904583 | 0.78 | CYP19A1 (0.38) | CYP2D6CYP2C9GRIN2BCYP19A1PTGIR | |
| SCHEMBL904431 | 0.78 | CYP19A1 (0.43) | CYP2D6CYP2C9GRIN2BBCHECYP19A1 | |
| SCHEMBL904514 | 0.78 | TSHR (0.45) | — | |
| SCHEMBL27928039 | 0.78 | PTGIR (0.59) | BCHEMAOBACHEPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621899-B1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-10-21 | — | — | EP | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| EP-2621899-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044046-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | OPRK1, OPRM1, OPRL1 | CYP2D6 708/4885CYP2C9 1834/4885GRIN2B 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.